Ann: Phosphagenics Arbitration Award Issued, page-139

BD
What was a complete farce was that:
1Elements of fraud were apparent in the Agila development of the improved TPM daptomycin injectable with patent priority dates listed for that product before the product had been licensed to them for development a few months later.
2.Shareholders were lead to believe that everything was progressing well with the Mylan injectable right up to the time of the arbitration advice.
3.Corrs and its experts got this so horribly wrong and could not see a no win result ever emerging[refer last ditch capital raising].
4.Mylan can now claim it has been the injured party in this matter and can stick all sorts of loaded costs to the POH account.